News und Analysen

In this podcast, Motley Fool host Deidre Woollard talks about the art of failing with Amy Edmondson, the Novartis Professor of Leadership and Management at the Harvard Business School, and author of

Eli Lilly (NYSE: LLY) has been on a tear this past year, rising up to become the most valuable healthcare stock in the world. It soared past UnitedHealth Group and other top healthcare companies in

Medtronic (NYSE: MDT) is a leading medical device company that aims to simplify patients' everyday lives. And with a broad presence that spans 150 countries, treating more than 70 health conditions

Investing in stocks is a great way for most people to grow their wealth over time. However, all stocks aren't created equal. Some are unlikely to deliver anything resembling solid returns over the

It's official: The S&P 500 is in a bull market after reaching a new all-time high last month. The index actually has been in this positive market phase ever since it started recovering from its bear

Pharmaceutical giant AbbVie (NYSE: ABBV) is getting used to life without Humira. Not literally, but the former global top-seller did lose patent exclusivity last year, and sales plummeted as cheaper

High-yielding dividend stocks can make for attractive investments given the potential income they can generate for your portfolio. But there is often a trade-off when it comes to high payouts, as

Those looking to invest in stocks can sometimes seem spoiled for choices. There are all kinds of businesses in the equity markets that seem intriguing. However, upon closer inspection, many of these

Every long-term investor should have at least some healthcare stocks in their portfolio. People will always need care, and the industry constantly looks for new and better ways to provide it

Shares of Medtronic (NYSE: MDT) climbed as much as 3.3% early Tuesday, and then settled to close up around 1.7%, after the medical-device company announced strong fiscal third-quarter results and

Image source: The Motley Fool.

Medtronic (NYSE: MDT)Q3 2024 Earnings CallFeb 20, 2024, 8:00 a.m. ET

Ryan Weispfenning

Continue reading

Source Fool.com

Vertex Pharmaceuticals (NASDAQ: VRTX) has wowed investors in recent times as it's expanded beyond its specialty area of cystic fibrosis (CF) treatment. The company launched Casgevy, a one-time

In a sense, every investor is a growth investor. If you focus on valuation, you want to find bargain stocks that will grow more in the future than in the past. If you're looking for income, you'll

Vertex Pharmaceuticals (NASDAQ: VRTX) is the global leader in cystic fibrosis (CF) treatment, and that specialty has helped it generate billions of dollars in earnings. But the company has also

Hot off the approval of its gene therapy for a pair of rare hereditary blood disorders, Vertex Pharmaceuticals (NASDAQ: VRTX) will soon have another therapy up for approval, and the financial

Dividends never go out of style, but some dividend stocks can. That's how some investors might feel about Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY) these days. Both companies have

Amgen (NASDAQ: AMGN) is one of the largest drug manufacturers in the world, with a market cap of more than $150 billion. It pays a dividend, has been growing steadily over the years, and has many

Shares of Sarepta Therapeutics (NASDAQ: SRPT) were soaring 10.4% higher as of 10:58 a.m. ET on Friday. The big gain came after the biopharmaceutical company announced that the U.S. Food and Drug

Equity markets can be highly volatile in the short run. Where the S&P 500 might land in the next six months is anyone's guess. However, over a decade, major indexes tend to move steadily in the

Many people make it a New Year's resolution to start investing -- a laudable goal. The good news is that doing so doesn't require millions of dollars in the bank. Even with $500, a relatively modest

I've been a big fan of Vertex Pharmaceuticals (NASDAQ: VRTX), and the biotech stock has made me a lot of money throughout the years. Vertex continues to enjoy a virtual monopoly in treating cystic

Shares of QuidelOrtho (NASDAQ: QDEL) were crashing 31.4% lower as of 11:30 a.m. ET on Wednesday. The huge decline came after the in vitro diagnostics company announced its 2023 full-year and